These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36384251)

  • 1. Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response.
    Jallouk AP; Gouni S; Westin J; Feng L; Mistry H; Steiner RE; James J; Noorani M; Horowitz S; Puebla-Osorio N; Fayad LE; Iyer SP; Hawkins M; Flowers CR; Ahmed S; Nastoupil LJ; Kebriaei P; Shpall EJ; Neelapu SS; Nieto Y; Strati P
    Haematologica; 2023 Apr; 108(4):1163-1167. PubMed ID: 36384251
    [No Abstract]   [Full Text] [Related]  

  • 2. Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas.
    Reagan PM; Friedberg JW
    Future Oncol; 2021 Apr; 17(11):1269-1283. PubMed ID: 33448873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Choe JH; Abdel-Azim H; Padula WV; Abou-El-Enein M
    JAMA Netw Open; 2022 Dec; 5(12):e2245956. PubMed ID: 36520440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma.
    Papadouli I; Mueller-Berghaus J; Beuneu C; Ali S; Hofner B; Petavy F; Tzogani K; Miermont A; Norga K; Kholmanskikh O; Leest T; Schuessler-Lenz M; Salmonson T; Gisselbrecht C; Garcia JL; Pignatti F
    Oncologist; 2020 Oct; 25(10):894-902. PubMed ID: 32339368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
    Locke FL; Ghobadi A; Jacobson CA; Miklos DB; Lekakis LJ; Oluwole OO; Lin Y; Braunschweig I; Hill BT; Timmerman JM; Deol A; Reagan PM; Stiff P; Flinn IW; Farooq U; Goy A; McSweeney PA; Munoz J; Siddiqi T; Chavez JC; Herrera AF; Bartlett NL; Wiezorek JS; Navale L; Xue A; Jiang Y; Bot A; Rossi JM; Kim JJ; Go WY; Neelapu SS
    Lancet Oncol; 2019 Jan; 20(1):31-42. PubMed ID: 30518502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma.
    Badar T; Johnson BD; Hamadani M
    Bone Marrow Transplant; 2021 Mar; 56(3):683-685. PubMed ID: 32782349
    [No Abstract]   [Full Text] [Related]  

  • 7. Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphoma.
    Othman T; Baird JH; Pak S; Mei M; Herrera AF; Mansour J; Shouse G; Sahebi F; Spielberger R; Cai JL; Farol L; Godfrey J; Kallam A; Phillips T; Popplewell L; Siddiqi T; Forman S; Budde LE
    Br J Haematol; 2024 Jul; 205(1):368-372. PubMed ID: 38797530
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety of axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma in an elderly intercity population.
    Shapiro LC; Mustafa J; Lombardo A; Khatun F; Joseph F; Gillick K; Naik A; Elkind R; Abreu M; Fehn K; de Castro A; Pradhan K; Binakaj D; Nelson R; Paroder M; Uehlinger J; Gritsman K; Alejandro Sica R; Kornblum N; Shastri A; Mantzaris I; Bachier-Rodriguez L; Verma A; Braunschweig I; Goldfinger M
    Bone Marrow Transplant; 2021 Jul; 56(7):1761-1763. PubMed ID: 33846558
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma.
    Bouchkouj N; Zimmerman M; Kasamon YL; Wang C; Dai T; Xu Z; Wang X; Theoret M; Purohit-Sheth T; George B
    Oncologist; 2022 Jul; 27(7):587-594. PubMed ID: 35403693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
    Jacobson CA; Chavez JC; Sehgal AR; William BM; Munoz J; Salles G; Munshi PN; Casulo C; Maloney DG; de Vos S; Reshef R; Leslie LA; Yakoub-Agha I; Oluwole OO; Fung HCH; Rosenblatt J; Rossi JM; Goyal L; Plaks V; Yang Y; Vezan R; Avanzi MP; Neelapu SS
    Lancet Oncol; 2022 Jan; 23(1):91-103. PubMed ID: 34895487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
    Halford Z; Anderson MK; Bennett LL
    Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review.
    Locke FL; Go WY; Neelapu SS
    JAMA Oncol; 2020 Feb; 6(2):281-290. PubMed ID: 31697310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy.
    Spiegel JY; Dahiya S; Jain MD; Tamaresis J; Nastoupil LJ; Jacobs MT; Ghobadi A; Lin Y; Lunning M; Lekakis L; Reagan P; Oluwole O; McGuirk J; Deol A; Goy A; Vu K; Andreadis C; Munoz J; Bennani NN; Vose JM; Dorritie KA; Neelapu SS; Locke FL; Rapoport AP; Hill BT; Miklos DB
    Blood; 2021 Apr; 137(13):1832-1835. PubMed ID: 33156925
    [No Abstract]   [Full Text] [Related]  

  • 14. Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy.
    Chow VA; Gopal AK; Gauthier J; Tseng YD; Turtle CJ; Maloney DG; Shadman M
    Blood Adv; 2020 Oct; 4(19):4869-4872. PubMed ID: 33031539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of hypoalbuminemia on the prognosis of relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel.
    Melody M; Gandhi S; Rahman ZA; Lengerke-Diaz P; Gannon N; Rosenthal A; Truong T; Novo M; Brandes E; Lange G; Estby B; Johnston P; Ansell S; Bennani NN; Paludo J; Bisneto JV; Ayala E; Tun HW; Murthy HS; Roy V; Foran J; Castro J; Lin Y; Kharfan-Dabaja MA
    Eur J Haematol; 2021 Jul; 107(1):48-53. PubMed ID: 33655560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study.
    Chiappella A; Casadei B; Chiusolo P; Di Rocco A; Ljevar S; Magni M; Angelillo P; Barbui AM; Cutini I; Dodero A; Bonifazi F; Tisi MC; Bramanti S; Musso M; Farina M; Martino M; Novo M; Grillo G; Patriarca F; Zacchi G; Krampera M; Pennisi M; Galli E; Martelli M; Ferreri AJM; Ferrari S; Saccardi R; Bermema A; Guidetti A; Miceli R; Zinzani PL; Corradini P
    Leukemia; 2024 May; 38(5):1107-1114. PubMed ID: 38459167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma.
    Cohen JA; Ghobadi A
    Expert Rev Anticancer Ther; 2022 Sep; 22(9):903-914. PubMed ID: 35786133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma.
    Neelapu SS; Jacobson CA; Oluwole OO; Munoz J; Deol A; Miklos DB; Bartlett NL; Braunschweig I; Jiang Y; Kim JJ; Zheng L; Rossi JM; Locke FL
    Blood; 2020 Jun; 135(23):2106-2109. PubMed ID: 32181801
    [No Abstract]   [Full Text] [Related]  

  • 19. New Second-Line Treatment for B-Cell Lymphoma.
    Aschenbrenner DS
    Am J Nurs; 2022 Aug; 122(8):23. PubMed ID: 35862599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States.
    Maziarz RT; Yang H; Liu Q; Wang T; Zhao J; Lim S; Lee S; Dalal A; Bollu V
    Leuk Lymphoma; 2022 Sep; 63(9):2052-2062. PubMed ID: 35422192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.